Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

Toonaangevende leiders

Alle informatieOndernemingenMarktenEconomie & ForexgrondstoffenRenteToonaangevende leidersFinanciŽle professionalAgendaSectoren 
HomepaginaAl het nieuwsHet meest gelezen nieuwsBiografieŽn van de Leiders
Overzicht 
Charles A. Rowland is on the board of PsiOxus Therapeutics Ltd. and 7 other companies.

Mr. Rowland previously was President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc., Chief Operating & Financial Officer at Breakaway Technologies, Inc., Finance Director for Bristol Myers Squibb Co., Co-Chief Executive Officer, CFO & Vice President at Endo Pharmaceuticals, Inc., Chief Financial Officer for Biovail Corp., Chief Financial Officer & Vice President of Shire ViroPharma, Inc., Chief Financial Officer, Treasurer & Executive VP for Endo Health Solutions, Inc., Vice President-Finance & Global Supply at Pharmacia Corp., Chief Financial Officer & Senior Vice President at Biovail Pharmaceuticals LLC and Vice President-Planning & Decision Support at Novartis Pharmaceuticals Corp.

Mr. Rowland received an MBA from Rutgers State University of New Jersey and an undergraduate degree from St. Joseph's University.


Posities en verantwoordelijkheden van Charles A. Rowland 
NaamTitel Van
Blueprint Medicines Corporation
(Biotechnologie & Medisch Onderzoek)
Independent Director 2015
Generation Bio Co.
(Biotechnologie & Medisch Onderzoek)
Independent Director 2018
Viking Therapeutics, Inc.
(Biotechnologie & Medisch Onderzoek)
Independent Director 2017
Orchard Therapeutics plc
(Farmaceutische producten)
Independent Non-Executive Director 2018
Nabriva Therapeutics plc
(Biotechnologie & Medisch Onderzoek)
Independent Director 2017
PsiOxus Therapeutics Ltd. Non-Executive Director 2017
Financial Executives International Philadelphia Chapter Director -
Orchard Therapeutics (Europe) Ltd. Independent Director 2018


Belangnemingen van Charles A. Rowland 
NaamAandelen%Totale waarde
Generation Bio Co. (GBIO)
(Biotechnologie & Medisch Onderzoek)
101 0350,18%2 525 875 USD
Blueprint Medicines Corporation (BPMC)
(Biotechnologie & Medisch Onderzoek)
5 8120,0099%542 085 USD
Viking Therapeutics, Inc. (VKTX)
(Biotechnologie & Medisch Onderzoek)
30 0000,038%198 300 USD
Orchard Therapeutics PLC12 2940,013%33 931 USD
Nabriva Therapeutics plc (NBRV)
(Biotechnologie & Medisch Onderzoek)
23 7730,048%25 199 USD


Charles A. RowlandPersoonlijk netwerk 
Meest gelezen nieuws 
15/09BRAD SMITH : Microsoft kondigt inkoop van eigen aandelen aan tot $60 mrd, verhoogt dividend
MR
13/09MARTIN SORRELL : Sorrell's S4 Capital verhoogt winstverwachting tot 40%
MR
14/09STEPHEN SCHERR : Goldman Sachs benoemt Coleman als nieuwe CFO, ter vervanging van Scherr
MR
15/09ILHAM KADRI : Activist Bluebell Capital wil ontslag CEO Solvay
AM
Meer nieuws


© 2021 People and Ownership :   
Charles A. Rowland Verbindingen